Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 310-318

  Osugi, Jun ^a   Yamaura, Takumi ^a   Muto, Satoshi ^a   Okabe, Naoyuki ^a   Matsumura, Yuki ^a   Hoshino, Mika ^a   Higuchi, Mitunori ^a   Suzuki, Hiroyuki ^a   Gotoh, Mitsukazu ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

ATP citrate lyase; Glucose transporter 1; Non small cell lung cancer; Prognosis

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; GLUCOSE TRANSPORTER 1; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; CANCER STAGING; GENE EXPRESSION; GENETICS; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATP CITRATE (PRO-S)-LYASE; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR BURDEN;

EID: 84929505028     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.004     Document Type: Article

References (35)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Sawabata N., Miyaoka E., Asamura H., Nakanishi Y., Equchi K., Mori M., et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 2011, 6:1229-1235.
3. Furuta E., Okuda H., Kobayashi A., Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010, 1805:141-152.
4. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927, 8:519-530.
5. Medes G., Thomas A., Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953, 13:27-29.
6. Brahimi-Horn M.C., Chiche J., Pouysségur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007, 19:223-229.
7. Kuhajda F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16:202-208.
8. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-1372.
9. Grover-McKay M., Walsh S.A., Seftor E.A., Thomas P.A., Hendrix M.J. Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 1998, 4:115-120.
10. Sakashita M., Aoyama N., Minami R., Maekawa S., Kuroda K., Shirasaka D., et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer 2001, 37:204-209.
11. Varis A., Wolf M., Monni O., Vakkari M.L., Kokkola A., Moskaluk C., et al. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002, 62:2625-2629.
12. Yahagi N., Shimano H., Hasegawa K., Ohashi K., Matsuzaka T., Najima Y., et al. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005, 41:1316-1322.
13. Minami K., Saito Y., Imamura H., Okamura A. Prognostic significance of p53, Ki-67, VEGF and GLUT1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38:51-57.
14. Anderson S., Eilertsen M., Donnem T., Al-Shibli K., Al-Saad S., Busund L.T., et al. Diverging prognostic impacts of hypoxia markers according to NSCLC histology. Lung Cancer 2011, 72:294-302.
15. Maki Y., Soh J., Ichimura K., Shien K., Furukawa M., Muraoka T., et al. Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. Oncol Rep 2013, 29:133-140.
16. Meijer T.W., Schuurbiers O.C., Kaanders J.H., Looijen-Salamon M.G., de Geus-Oei L.F., Verhagen A.F., et al. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer 2012, 76:316-323.
17. Sasaki H., Shitara M., Yokota K., Hirosaka Y., Moriyama S., Yano M., et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol Med Res 2012, 5:599-602.
18. Migita T., Narita T., Nomura K., Miyagi E., Inazuka F., Matsuura M., et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008, 68:8547-8554.
19. Camp R.L., Charette L.A., Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000, 80:1943-1949.
20. DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007, 104:19345-19350.
21. Zaidi N., Swinnen J.V., Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res 2012, 72:3709-3714.
22. Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., et al. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell 2013, 51:506-518.
23. Zu X.Y., Zhang Q.H., Liu J.H., Cao R.X., Zhong J., Yi G.H., et al. ATP citrate lyase inhibitors as novel cancer therapeutic agent. Recent Pat Anticancer Drug Discov 2012, 7:154-167.
24. Ralser M., Wamelink M.M., Struys E.A., Joppih C., Krobitsch S., Jakobs C., et al. A catabolic block does not sufficiently explain how 2-deoxy-d-glucose inhibits cell growth. Proc Natl Acad Sci U S A 2008, 105:17807-17811.
25. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
26. Bauer D.E., Hatzivassiliou G., Zhao F., Andreadis C., Thompson C.B. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005, 24:6314-6322.
27. Hunter A., Hendrikse A., Renan M., Abratt R. Does the tumor microenvironment influence radiation-induced apoptosis?. Apoptosis 2006, 11:1727-1735.
28. Moellering R.E., Black K.C., Krishnamuty C., Baggett B.K., Stafford P., Rain M., et al. Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis 2008, 25:411-425.
29. Migita T., Ruiz S., Fornari A., Fiorentino M., Priolo C., Zadra G., et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009, 101:519-532.
30. Yohena T., Yoshino I., Takenaka T., Kameyama T., Ohba T., Kuniyoshi Y., et al. Upregulation of hypoxia-inducible factor-1alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol 2009, 4:284-290.
31. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Mailty A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001, 276:9519-9525.
32. Furuta E., Pai S.K., Zhan R., Bandyopadhyay S., Watanabe M., Mo Y.Y., et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008, 68:10003-10011.
33. Cerfolio R.J., Bryant A.S., Ohja B., Bratolucci A.A. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005, 130:151-159.
34. Berghmans T., Dusart M., Pasesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
35. Kaira K., Serizawa M., Koh Y., Takahashi T., Yamaguchi A., Hanaoka H., et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 2014, 83:197-204.